Onset of drug resistance in NSCLC EGFR-mutated patients undergoing first-line tyrosine kinase inhibitors treatment usually occurs between 9 and 12 months of therapy (Chen et al. 2019), which leads to the need to follow as closely as possible the evolving of the disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.